Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on ITCI. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $132.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $106.23.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Friday. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. The business has a 50-day moving average of $129.71 and a 200 day moving average of $102.19. Intra-Cellular Therapies has a 12 month low of $64.09 and a 12 month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Equities research analysts anticipate that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.

Institutional Trading of Intra-Cellular Therapies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company raised its stake in Intra-Cellular Therapies by 1.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock worth $1,614,000 after acquiring an additional 283 shares in the last quarter. Captrust Financial Advisors grew its holdings in shares of Intra-Cellular Therapies by 47.0% during the third quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company’s stock worth $589,000 after purchasing an additional 2,572 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $280,000. Janus Henderson Group PLC lifted its holdings in shares of Intra-Cellular Therapies by 6.4% in the 3rd quarter. Janus Henderson Group PLC now owns 42,729 shares of the biopharmaceutical company’s stock valued at $3,126,000 after purchasing an additional 2,568 shares during the last quarter. Finally, Quarry LP lifted its holdings in shares of Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,300 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.